Product
UCB7665
Aliases
rozanolixizumab
Name
RYSTIGGO
INN Name
ROZANOLIXIZUMAB
FDA Approved
Yes
1 clinical trial
1 organization
1 indication
1 document
Indication
ThrombocytopeniaClinical trial
A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune ThrombocytopeniaStatus: Completed, Estimated PCD: 2019-02-04
Document
DailyMed Label: RYSTIGGOOrganization
UCB, Inc.